Matches in Nanopublications for { ?s ?p "[In NHLs, WT1 was positive in 4 of 5 (80%) Burkitt lymphomas, 9 of 12 (75%) ALK-positive ALCLs, 3 of 6 (50%) lymphoblastic lymphomas (2 of 4 T-cell, 1 of 2 B-cell), 14 of 31 (45%) ALK-negative ALCLs, 6 of 18 (33%) DLBCLs, and 1 of 6 (17%) cutaneous ALCLs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- NP257847.RAZuJHOCj9pMkn4H4ByHEiZDA-MO4zstIr33czRKhw8OE130_assertion description "[In NHLs, WT1 was positive in 4 of 5 (80%) Burkitt lymphomas, 9 of 12 (75%) ALK-positive ALCLs, 3 of 6 (50%) lymphoblastic lymphomas (2 of 4 T-cell, 1 of 2 B-cell), 14 of 31 (45%) ALK-negative ALCLs, 6 of 18 (33%) DLBCLs, and 1 of 6 (17%) cutaneous ALCLs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP257847.RAZuJHOCj9pMkn4H4ByHEiZDA-MO4zstIr33czRKhw8OE130_provenance.
- assertion description "[In NHLs, WT1 was positive in 4 of 5 (80%) Burkitt lymphomas, 9 of 12 (75%) ALK-positive ALCLs, 3 of 6 (50%) lymphoblastic lymphomas (2 of 4 T-cell, 1 of 2 B-cell), 14 of 31 (45%) ALK-negative ALCLs, 6 of 18 (33%) DLBCLs, and 1 of 6 (17%) cutaneous ALCLs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP372890.RAdXLXpXDlaXPTN7158knS4usQc1JB7or9IdBdZVjqxWQ130_assertion description "[In NHLs, WT1 was positive in 4 of 5 (80%) Burkitt lymphomas, 9 of 12 (75%) ALK-positive ALCLs, 3 of 6 (50%) lymphoblastic lymphomas (2 of 4 T-cell, 1 of 2 B-cell), 14 of 31 (45%) ALK-negative ALCLs, 6 of 18 (33%) DLBCLs, and 1 of 6 (17%) cutaneous ALCLs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP372890.RAdXLXpXDlaXPTN7158knS4usQc1JB7or9IdBdZVjqxWQ130_provenance.
- NP416477.RAlFjgFwb7NCC5G4enPDgBRwRxA6TzobMIvpVqkJIWYdE130_assertion description "[In NHLs, WT1 was positive in 4 of 5 (80%) Burkitt lymphomas, 9 of 12 (75%) ALK-positive ALCLs, 3 of 6 (50%) lymphoblastic lymphomas (2 of 4 T-cell, 1 of 2 B-cell), 14 of 31 (45%) ALK-negative ALCLs, 6 of 18 (33%) DLBCLs, and 1 of 6 (17%) cutaneous ALCLs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP416477.RAlFjgFwb7NCC5G4enPDgBRwRxA6TzobMIvpVqkJIWYdE130_provenance.
- NP635066.RAhHLotdTUI-zdQGsAJp9i4J07u8KREP-_MeEwBqGKBQU130_assertion description "[In NHLs, WT1 was positive in 4 of 5 (80%) Burkitt lymphomas, 9 of 12 (75%) ALK-positive ALCLs, 3 of 6 (50%) lymphoblastic lymphomas (2 of 4 T-cell, 1 of 2 B-cell), 14 of 31 (45%) ALK-negative ALCLs, 6 of 18 (33%) DLBCLs, and 1 of 6 (17%) cutaneous ALCLs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP635066.RAhHLotdTUI-zdQGsAJp9i4J07u8KREP-_MeEwBqGKBQU130_provenance.
- NP494879.RAdM04uSFGDuruhSsbSupz-DSmlZsc3ltr5h6mE_blJMY130_assertion description "[In NHLs, WT1 was positive in 4 of 5 (80%) Burkitt lymphomas, 9 of 12 (75%) ALK-positive ALCLs, 3 of 6 (50%) lymphoblastic lymphomas (2 of 4 T-cell, 1 of 2 B-cell), 14 of 31 (45%) ALK-negative ALCLs, 6 of 18 (33%) DLBCLs, and 1 of 6 (17%) cutaneous ALCLs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP494879.RAdM04uSFGDuruhSsbSupz-DSmlZsc3ltr5h6mE_blJMY130_provenance.
- NP494881.RAIKt-GwpfH_HA50KMIKOTuS8Impj4y0QAd3gztYL2fzo130_assertion description "[In NHLs, WT1 was positive in 4 of 5 (80%) Burkitt lymphomas, 9 of 12 (75%) ALK-positive ALCLs, 3 of 6 (50%) lymphoblastic lymphomas (2 of 4 T-cell, 1 of 2 B-cell), 14 of 31 (45%) ALK-negative ALCLs, 6 of 18 (33%) DLBCLs, and 1 of 6 (17%) cutaneous ALCLs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP494881.RAIKt-GwpfH_HA50KMIKOTuS8Impj4y0QAd3gztYL2fzo130_provenance.